142 related articles for article (PubMed ID: 27681506)
1. Increased interleukin-35 expression in tumor-infiltrating lymphocytes correlates with poor prognosis in patients with breast cancer.
Zhao Z; Chen X; Hao S; Jia R; Wang N; Chen S; Li M; Wang C; Mao H
Cytokine; 2017 Jan; 89():76-81. PubMed ID: 27681506
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
3. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.
Lee SJ; Hwang CS; Kim YK; Lee HJ; Ahn SJ; Shin N; Lee JH; Shin DH; Choi KU; Park DY; Lee CH; Huh GY; Sol MY; Lee HJ; Gong G; Kim JY; Kim A
Cancer Res Treat; 2017 Apr; 49(2):313-321. PubMed ID: 27456948
[TBL] [Abstract][Full Text] [Related]
4. Upregulated IL-19 in breast cancer promotes tumor progression and affects clinical outcome.
Hsing CH; Cheng HC; Hsu YH; Chan CH; Yeh CH; Li CF; Chang MS
Clin Cancer Res; 2012 Feb; 18(3):713-25. PubMed ID: 22186257
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating CD45RO(+) memory cells are associated with a favorable prognosis breast cancer.
Yajima R; Yajima T; Fujii T; Yanagita Y; Fujisawa T; Miyamoto T; Tsutsumi S; Iijima M; Kuwano H
Breast Cancer; 2016 Jul; 23(4):668-74. PubMed ID: 26071015
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
[TBL] [Abstract][Full Text] [Related]
7. CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes.
Liu F; Lang R; Zhao J; Zhang X; Pringle GA; Fan Y; Yin D; Gu F; Yao Z; Fu L
Breast Cancer Res Treat; 2011 Nov; 130(2):645-55. PubMed ID: 21717105
[TBL] [Abstract][Full Text] [Related]
8. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
[TBL] [Abstract][Full Text] [Related]
9. Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes.
Kim JY; Heo SH; Choi SK; Song IH; Park IA; Kim YA; Park HS; Park SY; Bang WS; Gong G; Lee HJ
Virchows Arch; 2017 Apr; 470(4):381-389. PubMed ID: 28185053
[TBL] [Abstract][Full Text] [Related]
10. Increased Brahma-related Gene 1 Expression Predicts Distant Metastasis and Shorter Survival in Patients with Invasive Ductal Carcinoma of the Breast.
Do SI; Yoon G; Kim HS; Kim K; Lee H; Do IG; Kim DH; Chae SW; Sohn JH
Anticancer Res; 2016 Sep; 36(9):4873-82. PubMed ID: 27630343
[TBL] [Abstract][Full Text] [Related]
11. [Tumor infiltrating regulatory T cells in human breast cancer and associated draining lymph nodes: an in-situ analysis].
Wang HY; Shi QF; Sun Y; He JJ; Wang YL
Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):95-100. PubMed ID: 23710915
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer stem cells phenotype and plasma cell-predominant breast cancer independently indicate poor survival.
Wei H; Fu P; Yao M; Chen Y; Du L
Pathol Res Pract; 2016 Apr; 212(4):294-301. PubMed ID: 26857534
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
14. Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor.
Benevides L; Cardoso CR; Tiezzi DG; Marana HR; Andrade JM; Silva JS
Eur J Immunol; 2013 Jun; 43(6):1518-28. PubMed ID: 23529839
[TBL] [Abstract][Full Text] [Related]
15. Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast.
Rathore AS; Kumar S; Konwar R; Srivastava AN; Makker A; Goel MM
Indian J Cancer; 2013; 50(3):239-44. PubMed ID: 24061465
[TBL] [Abstract][Full Text] [Related]
16. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast.
Leong PP; Mohammad R; Ibrahim N; Ithnin H; Abdullah M; Davis WC; Seow HF
Immunol Lett; 2006 Feb; 102(2):229-36. PubMed ID: 16246429
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
Chen S; Wang RX; Liu Y; Yang WT; Shao ZM
Int J Cancer; 2017 Mar; 140(6):1384-1395. PubMed ID: 27925176
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Pofut1 and activated Notch1 may be associated with poor prognosis in breast cancer.
Wan G; Tian L; Yu Y; Li F; Wang X; Li C; Deng S; Yu X; Cai X; Zuo Z; Cao F
Biochem Biophys Res Commun; 2017 Sep; 491(1):104-111. PubMed ID: 28709865
[TBL] [Abstract][Full Text] [Related]
19. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer.
Zhou S; Wang GP; Liu C; Zhou M
BMC Cancer; 2006 Sep; 6():231. PubMed ID: 17010208
[TBL] [Abstract][Full Text] [Related]
20. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M
Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
